Physician profile

Sergio R Mather

Endocrinology, Diabetes & Metabolism · Fort Myers, FL

NPI 1013915024

$3,608.92

in general payments reported to CMS, 2019-2025

32 companies · none reported in 2025

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $548.96 2019-2021
Novo Nordisk INC $531.16 2019-2021
Astrazeneca Pharmaceuticals LP $519.87 2019-2021
Lilly USA, LLC $249.09 2019-2021
Merck Sharp & Dohme LLC $228.70 2019-2021
Amgen INC. $211.46 2019-2020
Insulet Corporation $193.01 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $163.18 2019-2021
Mannkind Corporation $95.51 2019-2021
Valeritas, INC. $64.82 2019
Antares Pharma, INC. $64.36 2019-2021
Kowa Pharmaceuticals America, INC. $62.02 2019-2020
Ibsa Pharma INC. $60.37 2019-2020
Radius Health, INC. $60.18 2019-2020
Abbott Laboratories $55.40 2020
Show all 32 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sergio R Mather

$3,608.92

in general payments reported 2019-2025

Years
2019-2021
Top company
Sanofi-Aventis U.S. LLC

https://glasscript.com/doctor/137241/sergio-r-mather

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.